Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of either OAG or OHT study eye, requiring IOP-lowering treatment~* Participant is currently a nonsmoker and has not smoked any nicotine-containing products within the previous 6 months~Exclusion Criteria:~* Current or anticipated enrollment in another investigational drug or device study~* Females who are pregnant, nursing, or planning a pregnancy during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bimatoprost SR 10 μg (Type: EXPERIMENTAL): Participants will receive Bimatoprost SR 10 μg implant in the study eye on Day 1 and standard of care treatment in the fellow eye for the duration of the study.
- LUMIGAN 0.01% (Type: OTHER): Participants will receive topical LUMIGAN 0.01% in the study eye once daily starting evening Dose on Day 1 and standard of care treatment in the fellow eye for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).